Novo Nordisk Wins EU Nod for Hemophilia A Therapy Ahead of Pivotal London Strategy Day

CHMP recommends approval of denecimig, a first-of-its-kind pen for hemophilia A; Novo Nordisk shares rise 3.6% ahead of its Capital Markets Day.

European regulators have thrown their weight behind Novo Nordisk's experimental hemophilia A treatment, handing the Danish drugmaker a timely win as it prepares to unveil a sweeping strategic overhaul in London.

The Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency's human medicines arm, recommended approval of FREHEMGO (denecimig) for adults and children with hemophilia A, with or without inhibitors. Shares climbed 3.6% on the news, closing at EUR 37.74.

That endorsement — while not a final marketing authorization — carries considerable weight, since the European Commission typically follows CHMP opinions. Novo Nordisk expects to launch the drug in the first European markets in the fourth quarter of 2026, with a broader EU rollout to follow in early 2027.

A First-of-Its-Kind Dosing Option

Denecimig would become the first factor VIIIa mimetic to offer monthly, biweekly or weekly prophylaxis delivered through a prefilled single-use pen, according to the company. That flexibility is seen as a potential edge over existing therapies and could give Novo Nordisk a fresh revenue pillar beyond its obesity franchise, which has come under mounting pressure.

Supporting data from the Phase 3b FRONTIER5 trial showed no unexpected safety concerns over 26 weeks when adolescents and adults — both with and without inhibitors — switched directly from emicizumab to the denecimig pen.

Rebranding and a Culture Reset

The regulatory boost lands in a week packed with corporate news. On September 14, Novo Nordisk announced a comprehensive brand relaunch: the company will operate under the shortened name "Novo," paired with the tagline "Lasting Health Starts Now" and a new corporate culture dubbed "The Novo Way."

Chief executive Mike Doustdar, cited by Reuters, said the company needs to rethink its obesity strategy, and on Tuesday he urged staff to sharpen their customer focus. The timing is hardly coincidental — Novo Nordisk is repositioning itself after its shares have shed roughly 31% since hitting a 52-week high of EUR 54.86 in January.

Pipeline Setbacks and Paediatric Progress

Not everything has gone smoothly. In early September, the group halted two additional studies of its experimental cardiovascular drug ziltivekimab, according to Reuters — another blow to efforts to diversify beyond obesity and diabetes treatments. Set against those setbacks, the FREHEMGO recommendation weighs all the more heavily as a counterbalance.

There was encouraging news in the core business as well. Novo Nordisk released initial Phase 3 data from the STEP-Young study of weekly semaglutide combined with calorie reduction and increased physical activity in 165 children aged 6 to under 12 with obesity. After 68 weeks, 40.4% of treated children — assuming full adherence — were no longer classified as obese, Reuters reported.

AI Partnership Takes Shape

Alongside the brand refresh, Novo Nordisk is betting on artificial intelligence. On Wednesday, the company announced a collaboration with AI firm Anthropic aimed at accelerating drug development and advancing software-driven research. Novo Nordisk plans to test the Claude Science model in selected research and development workflows where the two companies' combined capabilities promise the greatest impact.

Buyback Machine Keeps Humming

Meanwhile, the share repurchase program continues without pause. As of September 11, Novo Nordisk had bought back a total of 33,084,179 B shares at an average price of DKK 281.89, representing a transaction volume of roughly DKK 9.33 billion. A week earlier, as of September 4, the tally stood at 32,034,179 shares at an average of DKK 281.63. The steady accumulation signals that Novo Nordisk is sticking with its capital return strategy despite the challenging share price environment.

What's Next for Investors

The stock remains well below its 50-day moving average — EUR 40.62 in one reading, EUR 40.73 in another — and has lost 14% year to date, a sign that the medium-term downtrend has yet to reverse. Pre-market trading showed the shares at EUR 37.77, nearly flat versus the prior day.

Attention now turns to September 21, when Novo Nordisk hosts its Capital Markets Day in London to present its revised corporate strategy in detail. A few days later, from September 28 to October 2, the company will take part in the annual meeting of the European Association for the Study of Diabetes in Milan. Between the new brand identity, the AI partnership, the hemophilia approval and its pipeline updates, Novo Nordisk will be looking to convince investors it has enough momentum to win back their confidence.